The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 11-membered azabicyclo ring.
[EN] NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
申请人:STANFORD RES INST INT
公开号:WO2009058120A1
公开(公告)日:2009-05-07
The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 1 1 - membered azabicyclo ring.
Antagonist activity at the alpha 3 beta 4 nicotinic acetylcholine receptor (nAChR) is thought to contribute to the antiaddictive properties of several compounds. However, truly selective ligands for the alpha 3 beta 4 nAChR have not been available. We report the discovery and SA R of a novel class of compounds that bind to the alpha 3 beta 4 nAChR and have no measurable affinity for the alpha 4 beta 2 or alpha 7 subtype. In functional assays the lead compound antagonized epibatidine-induced Ca2+ flux in alpha 3 beta 4-transfected cells in a noncompetitive manner.